Business context and reporting period
OncoGenex Pharmaceuticals, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2017. The filing is not a post-merger report from Achieve Life Sciences: OncoGenex was still the registrant, and its proposed all-stock merger with Achieve was pending. OncoGenex was a clinical-stage biopharmaceutical company with no product sales.
Key financial metrics
| Metric | Q1 2017 / March 31, 2017 | Comparable period / December 31, 2016 |
|---|---|---|
| Revenue | $0 | $2.94 million in Q1 2016 |
| Operating expenses | $3.35 million | $7.37 million in Q1 2016 |
| Net loss | $3.27 million; $0.11 per share | $3.71 million; $0.12 per share in Q1 2016 |
| Operating cash flow | -$9.00 million | -$9.09 million in Q1 2016 |
| Cash, cash equivalents and short-term investments | $16.45 million | $25.46 million at December 31, 2016 |
| Total assets | $17.90 million | $27.47 million at December 31, 2016 |
| Total liabilities | $2.01 million | $8.50 million at December 31, 2016 |
| Stockholders’ equity | $15.89 million | $18.97 million at December 31, 2016 |
There were no product sales, so conventional product gross margins are not applicable. Collaboration revenue recognized in Q1 2016 came from the remaining deferred Teva reimbursement; that balance had been fully recognized by 2016. The filing reports no material interest-rate exposure; it estimates a 1% rate increase would reduce investment fair value by about $0.1 million. No off-balance-sheet financing arrangements were reported.
Material changes versus prior periods
- R&D expense fell to $0.91 million from $4.64 million in Q1 2016, mainly as custirsen development ended and clinical activity and other costs declined.
- G&A expense rose to $2.53 million from $2.30 million, largely due to legal costs for the proposed Achieve merger.
- The company recorded a $0.10 million restructuring recovery, compared with $0.43 million of restructuring expense in Q1 2016. Prior workforce reductions eliminated 30 positions across 2016; the filing says 12 employees remained.
- Cash and investments declined by about $9.0 million from year-end. Operating cash use was partly offset by $9.48 million of investment maturities.
- Lower clinical accruals after discontinuing custirsen contributed to the decline in total liabilities.
Outlook, commentary, and risks
- Management believed available cash, cash equivalents and short-term investments would fund currently planned operations for at least 12 months, while warning that assumptions could prove wrong and additional capital might be needed sooner.
- The merger was targeted to close in mid-2017, subject to stockholder approval and other conditions. Achieve holders were expected to own about 75% of the combined company and OncoGenex holders about 25%. A May 3 amendment capped the contemplated reverse split at 20-for-1.
- Custirsen development was discontinued after its Phase 3 trials did not meet primary endpoints. OGX-225 was also discontinued. OncoGenex was seeking a partner to fund and develop apatorsen and did not plan further company-funded studies at that time.
- The final enrolled apatorsen Phase 2 Spruce-2 trial was expected to report results in the second half of 2017. Management cautioned that most apatorsen Phase 2 trials failed their predefined endpoints; a partner and further funding would be needed for additional development.
- Existing stockholders were expected to receive non-transferable contingent value rights tied to possible apatorsen-related milestones for five years after the merger. The filing says their value was uncertain; if no third-party term sheet was obtained by the end of the defined six-month period beginning in February 2017, the combined company would no longer be required to pursue an apatorsen deal under the CVR terms.
- Merger failure could result in termination fees and expenses, continued operating costs, or a possible board decision to liquidate. The company also disclosed NASDAQ’s minimum-bid-price deficiency and planned a reverse split if needed to regain compliance.
- Other key risks include clinical and regulatory failure, inability to secure a development partner or financing, merger delays, employee attrition, manufacturing and intellectual-property risks, and potential dilution. Management reported disclosure controls were effective at quarter-end.
Investor verification priorities
- Confirm whether the merger closed, its final exchange ratio and reverse-split terms, and the resulting ownership and dilution.
- Track actual cash burn, available liquidity, and whether the stated 12-month funding runway remained valid after the quarter.
- Review subsequent apatorsen trial results, any partnership or term sheet, and the final CVR terms and milestone economics.
- Verify the status of NASDAQ listing compliance and any financing, termination fees, or liquidation-related actions.
- Assess remaining contractual, patent-abandonment, lease, severance and other contingent obligations following discontinued programs.